Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Treasury Shares (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Treasury Shares for 7 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 79.45% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, up 79.45% year-over-year, with the annual reading at $1.3 million for FY2025, 79.45% up from the prior year.
  • Treasury Shares for Q4 2025 was $1.3 million at Kymera Therapeutics, down from $1.4 million in the prior quarter.
  • The five-year high for Treasury Shares was $1.4 million in Q3 2025, with the low at $37745.0 in Q4 2021.
  • Average Treasury Shares over 5 years is $570480.4, with a median of $527379.5 recorded in 2023.
  • The sharpest move saw Treasury Shares tumbled 65.72% in 2021, then soared 646.7% in 2022.
  • Over 5 years, Treasury Shares stood at $37745.0 in 2021, then skyrocketed by 646.7% to $281843.0 in 2022, then surged by 110.45% to $593140.0 in 2023, then grew by 26.38% to $749604.0 in 2024, then skyrocketed by 79.45% to $1.3 million in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $1.3 million, $1.4 million, and $1.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.